Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1994-10-04
1996-11-26
Webman, Edward J.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
514908, A61K 31185
Patent
active
055783139
ABSTRACT:
A method for treating neoplasia using sulfur-containing derivatives of carboxy-amino-amides, comprising vitaletheine and vitalethine and related compounds, is provided.
REFERENCES:
patent: 2722551 (1965-11-01), Snell
patent: 4060551 (1977-11-01), Uchikuga et al.
patent: 4102948 (1978-07-01), Feuer et al.
patent: 4218404 (1980-08-01), Feuer et al.
patent: 4552765 (1985-11-01), Mita et al.
patent: 4571430 (1986-02-01), Byrne
patent: 5370868 (1994-12-01), Knight et al.
Weisman et al, "Tricyclic Orthoacetamides and Orthopropionamides: Conformational Analysis and Sterochemical Effects upon .sup.13 C NMR Spectra", Tetrahdron Letters 22(44):4365-4368 (1981).
Sokolvsky et al, "On the Synthesis of Cystein Peptides", J. Am. Chem. Soc. 86:1202-1206 (1967).
Fifth Report by T. Pantev, "Synthesis of S-(omega-Carboxamidinoalkyl-)-Isothiocarbamides", Nauchnoizskd. Inst. Radiobiol. Radiats. Knigy. 5:57-62 (1975).
Merck Index, #221 (1974).
Garfinkel, "Is Aging Inevitable? The Intracellular Zinc Deficiency Hypothesis of Aging", Med-Hypothesis 19(2):117-37 (1986).
Meister & Anderson, Glutathione, pp. 743-760.
Chen et al, "The Role of Cholesterol in Malignancy", Prog. exp. Tumor Res. 22:275-316 (1978).
Gilbert, "Molecular and Cellular Aspects of Thiol-Disulfide Exchange", Adv. Enzymol. Metab. Rel. Area 63:69-172 (1990).
Ziegler, "Role of Reversible Oxidation-Reduction of Enzyme Thiols-Disulfides in Metabolic Regulation", Ann. Biochem. 54:305-329 (1985).
Chopra, "Sulfhydryl Groups and the Monodeiodination of Thyroxine to Triiodothyronine", Science 199:904-905 (1978).
Kawachi et al, "Solubilization and Purification of .beta.-Hydroxy-.beta.-methylglutaryl Coenzyme A Reductase from Rat Liver", Biochemistry 9:1700-1705 (1970).
Dotan et al, "Thiol-Disulfide-Dependent Interconversion of Active and Latent Forms of Rat Hepatic 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase", Biochemica et Biophysica Acta. 713:427-434 (1982).
Sabine, Chapter 1, "General Distribution and Importance of HMGCoA Reductase", pp. 3-18.
Rodwell et al, "Regulation of Hepatic 3-Hydroxy 3-Methylglutaryl-Coenzyme A Reductase", Adv. Enzymol. 38:373-412 (19 ).
De Flora et al, "Antioxidant Activity and Other Mechanisms of Thiols Involved in Chemoprevention of Mutation and Cancer", The American Journal of Medicine 91:3C-122S (1991).
Roederer et al, "Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine", Proc. Natl. Acad. Sci. USA 87:4884-4888 (1990).
Tsao et al, "Glutathione and glutathione S-transferases in clones of cultured rat liver epithelial cells that express varying activity of gamma-glutamyl transpeptidase", Mol. Carcinol. 2(3):144-9 (1989).
Dr oge et al, "Modulation of Lymphocyte Functions and Immune Response by Cysteine and Cysteine Derivatives", The American Journal of Medicine 91:3C-140S (1991).
Eck et al, "Elevated plasma glutamate concentrations in HIV-1-infected patients may contribute to loss of macrophage and lymphocyte functions", Int. Immunol. 1(4):367-72 (1989).
Fra nkov a, "The Effects Of Amino Acids with Sulfhydryl Groups On Herpes viruses In Vitro", . . . eta virol. 11:559-561, (1967).
Kalebic et al, "Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine", Proc. Natl. Acad. Sci. USA 88:986-990 (1991).
Eck et al, "Low Concentrations of Acid-Soluble Thiol (Cysteine) in the Blood Plasma of HIV-1-Infected Patients", Biol. Chem. Hoppe Segler 370:101-8 (1989).
Buhl et al, "Systemic Glutathione Deficiency in Symptom-Free HIV-Seropositive Individuals", The Lancet 1294-1297 (1989).
Guder et al, "The Influence of Thyroid Hormones on .beta.-Hydroxy-.beta.-Methylglutaryl-Coenzyme A Reductase of Rat Liver", European J. Biochem. 4:273-278 (1968).
Magee, "Post-translational process of ras proteins", Biochem. Soc. Trans. 19(5):875-6 (1989).
Schafer et al, "Genetic and Pharmacological Suppression of Oncogenic Mutations in RAS Genes of Yeast and Humans", Research Articles, pp. 379-385 (1989).
Gregg et al, "3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Cancer", Cholesterol and Cancer, Chapter 17, pp. 245-257 (19--).
Paukovits et al, "Protection From Arabinofuranosylcytosine and n-Mustart-Induced Myelotoxicity Using Hemoregulatory Peptide pGlu-Glu-Asp-Cys-Lys Monomer and Dimer", Blood 77(6):1313-1319 (1991).
Laerum et al, "The Dimer of Hemoregulatory Peptide (HP5B) Stimulates Mouse and Human Myelopoiesis in vitro", Exp. Hematol. 16:274-280 (1988).
Amery et al, "Levamisole and Immunotherapy: Some Theoretic and Practical Considerations and Their Relevance to Human Disease", Oncology 38:168-181 (1981).
Anderson et al, "The Use of Esters of N-Hydroxysuccinimide in Peptide Synthesis", J. Am. Chem. Soc. 86:1839-1842 (1964).
Garcia-Pe narrubia et al, "Antibacterial Activity of Human Natural Killer Cells", J. Exp. Med. 169:99-113 (1989).
Dessypris et al, "Increased Sensitivity to Complement of Erythroid and Myeloid Progenitors in Paroxysmal Nocturnal Hemoglobinuria", The New England Journal of Medicine 309(12):690-693 (1983).
Eck et al, "Elevated plasma glutamate concentrations in HIV-1-infected patients may contribute to loss of macrophage and lymphocyte functions", Int. Immunol. 1(4):367-372 (1989).
Suthanthiran et al, "Glutathione rgulates activation-dep. DNA syn. in highly purified normal human T lymphocites stimulated via the CD2 and CD3 antigens", Proc. Natl. Acad. Sci 87:3343 (1990).
Yudkoff et al, "Cysteamine Therapy in Cystinosis", New England J. Med. 304:141 (1981).
Zhang et al, "A Major Inducer of Anticarcinogenic Protective Enzymes from Broccoli: Isolation and Elucidation of Structure" 89:2399 (1992).
Goetz et al, "Clinical Management of Progressive Multifocal Benign and Malignant Melanomas of Horses with Oral Cimetidine".
Amitage et al, The Lancet, Apr. 21, 1979, "Antitumor Effect of Cimetidine".
Thorne, Lynch, Sheehan, "Cimetidine and Coumarin Therapy of Melanoma", The Lancet, Aug. 7, 1982, p. 328.
Osband et al, "Successful Tumour Immunotherapy with Cimetidine in Mice", The Lancet, Mar. 21, 1981, p. 636.
Flodgren et al, "Metastatic Malignant Melanoma: Regression Induced by Combined Treatment with Interferon [HulFN.alpha.(Le)] and Cimetidine", Br. J. Cancer 32:657 (1983).
Hill et al, Interferon and Cimetidine for Malignant Melanoma, New England J. Med., Feb. 3, 1982, p. 286.
Somogyi et al, "Cimetidine Reduces Procainamide Elimination", N. Engl. J. Med. 307:1080, Oct. 21.
Currie, "Effect of Autoimmunization with Irradicated Tumor Cells on Specific Cell-Mediated Immunity in Patients with Malignant Melanoma", Proc. Rory. Soc. Med. 65:144 (1972).
Oiry et al, "Synthesis and Radioprotective Activity of New Cysteamine and Cystamine Derivatives", J. Med. Chem. 29(11):2217-2225 (1989).
Knight Galen D.
Scallen Terence J.
The University of New Mexico
Webman Edward J.
LandOfFree
Therapeutic use of vitaletheine modulators in neoplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of vitaletheine modulators in neoplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of vitaletheine modulators in neoplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1971149